Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: True, the news hit hard last month that the so-called “Boston patients” - two men who received bone marrow transplants that appeared to rid them completely of the AIDS-causing virus - had relapsed and gone back onto antiretroviral treatment. But experts say the disappointment could lay the basis for important leaps forward in the search for a cure. “It’s a setback for the patients, of course, but an advance for the field because the field has now gained a lot more knowledge,” said Steven Deeks, a professor and HIV expert at the University of California, San Francisco. He and other experts say the primary practical message is that current tests designed to detect even very low levels of HIV present in the body are simply not sensitive enough. As well as having the human immunodeficiency virus (HIV), the Boston patients both also had a type of blood cancer called lymphoma, for which they were treated using bone marrow transplants - one man in 2008 and the other in 2010. They continued taking the antiretroviral AIDS drugs, but eight months after each patient’s transplant, doctors found they could not detect any sign of HIV in their blood. In the early part of 2013, both patients decided to stop taking their AIDS drugs and both appeared to remain HIV-free - prompting their doctors, Timothy Henrich and Daniel Kuritzkes from Boston’s Brigham and Women’s Hospital, to announce at a conference in July that they may have been cured. Yet in December came news that one of the men had begun to show signs of an HIV rebound by August, while the second patient had a relapse in November. Henrich said the virus’ comeback underlined how ingenious HIV can be in finding hiding places in the body to evade attack efforts by the immune system and by drug treatment. “Through this research we have discovered the HIV reservoir is deeper and more persistent than previously known and that our current standards of probing for HIV may not be sufficient,” he said, adding that both patients were “currently in good health” and back on antiretroviral therapy. Barely a decade ago, few HIV scientists would have dared put the words HIV and cure in the same sentence. Yet some intriguing and inspiring cases in recent years mean many now believe it is just a question of time before a cure is found. First was the now famous case of Timothy Ray Brown, the so-called “Berlin patient,” whose HIV was eradicated by a complex treatment for leukemia in 2007 involving the destruction of his immune system and a stem cell transplant from a donor with a rare genetic mutation that resists HIV infection. Such an elaborate, expensive and life-threatening procedure could never be used as a broad-spectrum approach for the world’s 34 million HIV patients. But the results in Brown focused scientific attention on a genetic mutation known as ‘CCR5 delta 32’ as a target for possible gene therapy treatment. Then last March, French scientists who followed 14 HIV-positive people known as the “Visconti patients”, who were treated very swiftly with HIV drugs but then stopped treatment, said that even after seven years off therapy, they were still showing no signs of the virus rebounding. That announcement came only weeks after news of the “functional cure” of an HIV-positive baby in Mississippi who received antiretroviral treatment for 18 months from the day she was born. By the time she was two this appeared to have stopped the virus replicating and spreading. A “functional cure” is when HIV is reduced to such low levels that it is kept at bay even without treatment, though the virus can still be detected in the body. Sharon Lewin, an HIV expert at Monash University in Australia, said all these developments, as well as the setback suffered by the Boston patients, inspired scientists to investigate many different approaches in the search for a cure. “We’ve learnt many things here - and one of the most important is that a tiny, tiny amount of virus can get the whole thing going again,” she told Reuters. “It’s a clear message that we need better ways to pick up the virus.”  Scientists are now more convinced than ever that a two-pronged approach which aims to firmly suppress the virus while bolstering the immune system provides the best way forward. “We need to attack in two ways - reduce the virus to very low levels and also to boost the immune response. We can’t do one without the other,” said Lewin. “So we still have to think of other creative ways to control HIV. And it’s still early days... before we can say which approach is likely to be the winner.” Claim: Relapse of 'cured' HIV patients spurs AIDS science on.
Example Output: Scientists seeking a cure for AIDS say they have been inspired, not crushed, by a major setback in which two HIV positive patients believed to have been cured found the virus re-invading their bodies once more.

Example Input: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company’s most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. “We are delighted with the final data,” Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration “to determine next steps” for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a “breakthrough” drug by the FDA last April based on initial data from the trial. The FDA grants “breakthrough” status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.
Example Output: Pfizer Inc’s experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study’s primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

Example Input: Paragraph: The 34-year-old from Costa Rica who lives in New York opted for plastic surgery on her nose and now feels ready for prime time on social media. “I definitely feel more comfortable right now with my looks,” Reynolds explained. “If I need to take a selfie, without a doubt, I would have no problem.”  Reynolds is one of a growing number of people who have turned to plastic surgeons to enhance their image. Others are  hiring specialized make-up artists in what may be an emerging selfie economy. Selfies, or self portraits, rose in popularity along with smartphones and social media sites such as Facebook, MySpace and Instagram as a mostly young adult crowd posted images of themselves. Now everyone from Hollywood stars to prime ministers takes selfies. Comedian Ellen DeGeneres posted a selfie with Hollywood A-listers at the Academy Awards on Twitter that became the most retweeted of all time. When Danish Prime Minister Helle Thorning-Schmidt’s snapped a selfie with President Barack Obama and British Prime Minister David Cameron at Nelson Mandela’s memorial service it caused a media sensation. For mere mortals, going under the scalpel to create a better selfie may not seem so extreme. Plastic surgeons in United States have seen a surge in demand for procedures ranging from eye-lid lifts to rhinoplasty, popularly known as a nose job, from patients seeking to improve their image in selfies and on social media. A poll by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) of 2,700 of its members showed that one in three had seen an increase in requests for procedures due to patients being more aware of their image in social media. They noted a 10 percent rise in rhinoplasty in 2013 over 2012, a 7 percent jump in hair transplants and 6 percent increase in eyelid surgery. “There has been a 25 percent increase over the past year and a half to two years. That is very significant,” Dr. Sam Rizk,  a plastic surgeon, said about his Manhattan practice. “They come in with their iPhones and show me pictures,” Rizk, 47, added. “Selfies are just getting to be so crazy. Rizk, who specializes in rhinoplasty, said not everyone who requests surgery needs it because a selfie produces a distorted image that does not represent how a person really looks. “We all will have something wrong with us on a selfie image,” he explained. “I refuse a significant proportion of patients with selfies because I believe it is not a real image of what they actually look like in person.”  Some patients get upset when Rizk tells them surgery is not necessary, and he knows they will simply go to another surgeon. “Too many selfies indicate a self obsession and a certain level of insecurity that most teenagers have. It just makes it worse,” he said. “Now they can see themselves in 100 images a day on Facebook and Instagram.”  New York make-up artist Ramy Gafni, who has worked with clients on selfies and online dating profile photos, suggests using clean makeup, well-defined eyebrows and a bit color on the lips to produce the best selfies. “You want to enhance your features, perfect your features but not necessarily change your features into something they are not,” he said. Dan Ackerman, senior editor with CNET which tests and reviews products, said the Internet is full of tips and advice on selfies. “There are apps that apply filters to your face that smooth out wrinkles ... or put artificial makeup.... There is a sub economy of tools and advice that have built up around this,” he added. Claim: Nip, tuck, click: Demand for U.S. plastic surgery rises in selfie era.
Example Output:
Dental hygienist Jennifer Reynolds was always self-conscious about her looks, never took selfies and felt uncomfortable being tagged in photographs posted on social media.